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Hemangioma in Long-Term Survivors Who Underwent
Hematopoietic Stem Cell Transplantation with
Radiation Therapy during Childhood or Adolescence
Takashi Koike,1 Noriharu Yanagimachi,2 Hiroyuki Ishiguro,1 Hiromasa Yabe,3 Miharu Yabe,4
Tsuyoshi Morimoto,1 Takashi Shimizu,2 Hiromitsu Takakura,1 Shunichi Kato3Radiation-induced cavernous hemangioma (RICH) is a late complication of cerebral radiation therapy. Long-
term survivors of hematopoietic stem cell transplantation (HSCT) who underwent radiation therapy could
be at increased risk for RICH. We investigated records of 68 patients who underwent HSCT during child-
hood or adolescence and were assessed by magnetic resonance imaging (MRI), including T2*-weighted im-
aging of the brain, annually for 5 years over a range of 6 to 29 years after HSCT. We developed a scoring and
grading system for RICH to monitor the process and the progress of radiologic changes. Among the 68 pa-
tients investigated, 28 (41.2%) were diagnosed with CH. All 28 patients had received total body irradiation as
a conditioning treatment for HSCTand/or cranial radiation therapy before HSCTas part of the treatment of
their primary disease. RICH was diagnosed in none of the patients who did not receive radiation (n5 19), in
46.2% of those who received 6 to 12 Gy (n5 39), and in all of those who received 18 to 36 Gy (n5 10). Total
RICH scores were correlated with higher radiation doses. Careful and long-term evaluationwith MRI, includ-
ing T2*-weighted imaging, is necessary for HSCT recipients who received radiation therapy before and/or
during HSCT.
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ScoreINTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
has been widely applied to treat a variety of malignant
and nonmalignant diseases in childhood. Advances in
transplantation practices and supportive care have led
to improved outcomes and have resulted in an incre-
asing number of long-term HSCT survivors [1-3].
The overall survival rate after HSCT in childhood is
now .50%, and more than 5,000 childhood HSCT
recipients are estimated to be currently surviving
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6/j.bbmt.2011.12.582adulthood survivors experience morbidity, which is
generally related to the treatment they received to
cure their original disease rather than to the disease it-
self, and treatment-related morbidity is extraordinarily
diverse [5].HSCTsurvivors are at significant risk of de-
veloping late complications after successful transplan-
tation during childhood [6]. In particular, radiation
therapy may be a cause of later complications, such as
secondary neoplasm [6], growth failure [7], thyroid
dysfunction [8], and gonadal dysfunction [9].
Cranial radiation therapy (CRT) has been an inte-
gral part of the treatment of patients with cranial tu-
mors, other solid tumors of the head, and disorders
with central nervous system involvement, as well as to
prevent central nervous system relapse in acute leuke-
mia. Known late complications of radiation therapy
include not only endocrine dysfunction, cognitive dete-
rioration, and secondary neoplasm, but also the risk of
developing cavernous hemangioma (CH). The preva-
lence of CH or cavernous malformation was found to
be as high as 0.5% in a large prospective cohort from
the general population without radiation exposure
[10]. Although these malformations were initially
thought to be congenital, in 1994, Ciricillo et al [11]
Biol Blood Marrow Transplant 18:1090-1098, 2012 1091RICH after HSCTreported seven patients with intracerebral cavernoma as
a possible consequence of radiation, and since then,
another 84 cases and reviews have been described [12].
The literature suggests that radiation doses .30
Gy are associated with a shorter latency period and
that younger age at the time of radiation exposure is
a risk factor for developing radiation-induced cavern-
ous hemangioma (RICH) [13]. However, despite the
increasing number of reported cases, the mechanisms
of CH formation after radiation are complex, and the
impacts of radiation dose, sex, and age at the time of ra-
diation therapy remain poorly understood. A longitu-
dinal study investigating the relationship between
HSCT and developing RICH in survivors of child-
hood HSCT has yet to be published. To evaluate the
prevalence of RICH, we performed a longitudinal ret-
rospective study of adult survivors of childhoodHSCT
at a single institution.PATIENTS AND METHODS
Patients
We investigated 147 patients who underwent
HSCT during childhood or adolescence at Tokai
University Hospital between March 1982 and July
2000 and had annual follow-up after HSCT. Inclusion
criteria were survival for at least 10 years after HSCT,
no previous history of brain disease before HSCT, and
annual brain magnetic resonance imaging (MRI)
studies between April 1, 2006, and July 31, 2011.
Among the 147 patients, 68 (35 males and 33
females) visited Tokai University Hospital annually
throughout the follow-up period and were enrolled in
this study. The remaining 79 patients were followed
up at Tokai University Hospital initially but then
received continuing follow-up at their referring hospi-
tals without T2*-weighted MRI; these patients were
excluded from this study.
The median age of the 68 patients at HSCT was 7
years (range, 0-24 years) and that at the last evaluation
was 28 years (range, 14-43 years). The median follow-
up duration after HSCT was 19 years (range, 10-28
years). Patient characteristics are summarized in
Table 1. Written informed consent was obtained
from all patients and/or parents. The study was ap-
provedbyTokaiUniversity’sClinical ResearchReview
Committee.
Transplantation Procedure
In addition to conventional chemotherapy, nine pa-
tients with acute lymphoblastic leukemia (ALL) and
one patient with non-Hodgkin lymphoma (NHL)
received prophylactic CRT (24 Gy in one patient and
18 Gy in nine patients) between 1 year and 9 years
beforeHSCT. In 54 patients, the consitioning regimen
comprised irradiation with or without cyclophospha-mide and/or other drugs. Between 6 and 12 Gy of total
body irradiation (TBI) for malignant diseases was given
in 3 to 6 fractions, and 6 to 8 Gy of thoracoabdominal
irradiation for nonmalignant diseases was given in
three or four fractions. The remaining 14 patients re-
ceived conditioning without irradiation.
The method of TBI delivery remained constant
during the period when those patients underwent
HSCT, whereas the method of CRT delivery varied
among the institutions in which those patients were
treated initially. Prophylaxis against graft-versus-host
disease varied during the study period and used meth-
otrexate, cyclosporine, or a combination of the two.
Brain MRI
The radiologic diagnosis of CH was made based
on MRI findings, including gradient-echo sequence
(T2*-weighted imaging) and contrast MRI with gado-
linium chelates, performed annually for 6 to 29 years
after HSCT. MRI was done using mainly a 1.5-T
and occasionally a 3-T superconducting MRI system.
Typical appearance on T2-weighted MRI was a pe-
ripheral rim of hypointense hemosiderin surrounding
a central core of heterogeneous reticulated signal,
often described as ‘‘popcorn-like.’’ The hypointense
ring may represent repeated subclinical intralesional
and perilesional hemorrhages leading to ferritin depo-
sition secondary to erythrocyte breakdown [14]. In
particular, T2*-weighted imaging of the brain is highly
sensitive for the detection of small CH.
CH Score
The patients were evaluated for CH number, size,
and distribution and for annual changes in these param-
eters. We developed a CH scoring system based on
MRI findings to monitor the process and the progress
of radiologic changes. CH size\3 mm was defined as
score1 (1 point), CH size 3 to 5mmas score2 (2 points),
CH size 6 to 8mm as score3 (3 points), andCH size$9
mm as score4 (4 points) (Figure 1).
CH Grade
Themagnitude of CHwas graded according to to-
tal CH score and the presence of mass effect as grade 0,
total score 0; grade I, total score 1-4; grade II, total
score 5-9; grade III, total score$10; or grade IV, total
score $5 and mass effect present.
Statistical Analysis
Because the data had a skewed distribution, values
are presented as median and range. Differences in
eight variables—sex, age at HSCT, age at first radia-
tion therapy, age at latest MRI, age at diagnosis of
CH, original disease, radiation dose to the head, and
type of transplantation—among groups were analyzed
by the Pearson c2 test or Fisher exact test. The
Table 1. Patient Characteristics
Total
Groups According to Total Cranial Radiation Dose
A (0 Gy) B (6-12 Gy) C (18-36 Gy)
Number of patients 68 19 39 10
Females/males, n 33/35 6/13 21/18 6/4
Primary disease, n
Malignant diseases
Acute lymphoblastic leukemia 18 0 9 9
Acute myelogenous leukemia 11 0 11 0
Chronic myelogenous leukemia 5 1 4 0
Juvenile myelomonocytic leukemia 1 0 1 0
Myelodysplastic syndrome 2 0 2 0
Non-Hodgkin lymphoma 4 0 3 1
Neuroblastoma 2 0 2 0
Yolk sac tumor 1 0 1 0
Nonmalignant diseases
Severe aplastic anemia 10 6 4 0
Others 14 12 2 0
Autologous/allogeneic HSCT, n 7/61 0/19 6/33 1/9
Age at HSCT, years, median (range) 7 (0-24) 5 (1-12) 9 (0-24) 10 (4-19)
Age at first irradiation, years, median (range) 8 (0-24) 9 (0-24) 6 (0-17)
Age at latest MRI, years, median (range) 28 (14-43) 24 (12-33) 29 (16-43) 28.5 (21-37)
Follow-up after HSCT, years, median (range) 19 (10-28) 16 (10-23) 20 (11-28) 18 (16-21)
1092 Biol Blood Marrow Transplant 18:1090-1098, 2012T. Koike et al.Mann-Whitney U test and the Kruskal-Wallis test
were used to compare differences between groups. A
Kaplan-Meier survival curve was constructed to assess
the probability of CH incidence, and the log-rank test
was used to compare probabilities. In multivariate
analyses, outcome comparisons were adjusted with
Cox proportional hazards models and tested by the
likelihood ratio test. All statistical analyses were per-
formed with SPSS version 19. A P value\.05 was con-
sidered statistically significant.RESULTS
Incidence of CH
CHwas diagnosed in 28 of the 68 patients (41.2%)
by MRI during the follow-up period (Table 2). TheFigure 1. CH scoring and grading system. This example case has a total Cprobability of developing CH at 25 years after
HSCT was 61.5% 6 9.1% by the Kaplan-Meier
method (Figure 2A). The median age at diagnosis of
CH was 27 years (range, 11-40 years). The median
age at HSCT was 9.5 years (range, 1-22 years), and
the median age at first irradiation treatment in the
patients diagnosed with CH was 7.5 years (range,
0-22 years).
Incidence and probability were further analyzed
according to several variables to evaluate risk factors
for CH (Table 2). Gender, type of transplantation
and age at the first irradiation did not give statistically
significant differences in frequency or in probability of
CH. However, compared with patients with nonma-
lignant diseases, those with malignant diseases in
which HSCT was indicated had a significantly higher
frequency of CH (59.1 versus 8.3%; P \ .001) andH score of 6 [a(score 3) 1 b(score 1) 1 c(score 2)] and CH grade II.
Table 2. Univariate Analysis of the Incidence of CH with the
Frequency and Probability of Developing CH by the Kaplan-
Meier Test
Category N
CH
Incidence,
n (%) P Valuea
Probability,
% P Valueb
Total 68 28 (41.2) 61.5 ± 9.1
Sex
Female 33 16 (48.5) NS 70.9 ± 11.2 NS
Male 35 12 (34.3) 75.6 ± 18.4
Primary disease
Malignant 44 26 (59.1) <.001 75.6 ± 8.6 <.001
Nonmalignant 24 2 (8.3) 6.2 ± 6.1
Type of transplantation
Autologous 7 4 (57.1) NS 61.9 ± 19.9 NS
Allogeneic 61 24 (39.3) 61.7 ± 10.8
Age at HSCT, years
<10 41 14 (34.2) NS 56.8 ± 12.8 <.05
$10 27 14 (51.9) 72.1 ± 11.3
Age at first radiation,
years
<10 28 16 (57.1) NS 68.1 ± 11.0 NS
$10 21 12 (57.1) 75.8 ± 11.8
Total cranial radiation
dose, Gy
0 19 0 (0) <.001 0 <.001
6-12 39 18 (46.2) 62.0 ± 10.1
18-30 10 10 (100) 100
NS indicates not significant.
aPearson’s c square test or Fisher exact test.
bLog-rank test (Kaplan-Meier).
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(75.6% 6 8.6% versus 6.2% 6 6.1%; P\ .001).
Age at HSCT showed a marginally significant
effect. Patients who underwentHSCTat age$15 years
had a slightly higher probability of developingCH than
did younger patients (56.8%6 12.8% versus 72.1%6Figure 2. Probabilty of developing CH after HSCT. (A) The probability of dev
HSCT. (B) Based on total cranial radiation dose, the probability was 0% in the p
the conditioning treatment for HSCT, 62.0%6 10.1% in those with a total cran
to 36 Gy. These differences are highly significant (P\.001).11.3%; P\ .05). The mean total cranial radiation dose
was 8.8 6 8.4 Gy in patients aged 0 to 9 years and
12.8 6 8.5 Gy in those aged $10 years (P 5 .058).
The patients were divided into three groups ac-
cording to total cranial radiation dose: group A, none
(n 5 19); group B, 6 to 12 Gy (n 5 39); and group
C, 18 to 36 Gy (n 5 10). CH was not detected in any
of the group A patients but was found in 46.2% of
the group B patients and in 100% of the group C pa-
tients; the intragroup differences were highly signifi-
cant (P \ .001) (Table 2). The probability of CH
was 0% in group A, 62.0% 6 10.1% in group B, and
100% in group C (P\ .001) (Table 2 and Figure 2B).
The results of Cox multivariate regression analysis
for developing CH are presented in Table 3. Of the
covariates shown to be significant in univariate analy-
sis, only cranial radiation dose was found to be signif-
icantly associated with CH risk (P\ .001).
CH Score and Grade
In the 28 patients with CH, the total CH score
at the latest MRI ranged from 1 to 19 points (median,
5 points). The total number of CH lesions in these pa-
tients was 115, including 75 lesions with a CH score of
1, 27 with a CH score of 2, four with a CH score of 3,
and four with a CH score of 5. Only 21 of the 115 le-
sions that were identified by T2*-weighted MRI
(18.3%) were visible on conventional T2-weighted
MRI. In particular, conventional T2-weighted MRI
could identify all nine lesions with a CH score of 3
or 4 but none of lesions with a CH score of 1 or 2.
The most common location of CH was supra-
tentorial (n 5 102; 88.7%), particularly in theeloping CH in the 68 study patients was 61.5%6 9.1% at 25 years after
atients who did not receive irradiation to the head before and/or during
ial radiation dose of 6 to 12 Gy, and 100% in those with a total dose of 18
Table 3. CoxMultivariate Regression Analysis for Developing
CH
HRa 95% CI P Value
Disease (malignant versus nonmalignant) 2.02 0.45-9.05 .360
Age at transplantation (<10 years versus
$10 years)
1.37 0.62-3.02 .435
Cranial radiation dose (0 versus 6-12 versus
19-36 Gy)
10.02 3.65-27.49 <.001
aHazard ratio.
Table 5. Localization of Infratentorial and Basal Ganglia CH
Lesions
CH Score Basal Ganglia Thalamus Midbrain Pons Cerebellum Total
1 1 1 2 4
2 4 4
3 2 2
4 1 2 3
Total 1 1 0 1 10 13
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subcortical and deep white matter (Table 4). Only 13
infratentorial and basal ganglia lesions (11.3%) were
identified, most of which were in the cerebellum
(10 of 13; 76.9%) (Table 5).
A significant correlation was found between the
latest total CH score and the total cranial radiation
dose (Figure 3). Neither age at HSCT nor age at the
first irradiation treatment were correlated with CH
score (data not shown). CH grade was 0 in 40 patients,
I in 14 patients, II in eight patients, III in four patients,
and IV in one patient.Changes in CH Score During the 5-Year
Observation Period
CH was identified on the initial MRI in 22 pa-
tients, and was newly identified in six patients during
the 5-year observation period. Mixed high and lowTable 4. Supratentorial Localization of CH Lesions
CH Score
Frontal
Lobe
Temporal
Lobe
Parietal
Lobe
Occipital
Lobe Total
Cerebral cortex
1 1 2 3 3 9
2 3 2 1 6
3
4 1 1
Subtotal 4 3 5 4 16
Subcortical white matter
1 15 5 12 3 35
2 6 5 11
3 1 1
4 1 1
Subtotal 21 6 18 3 48
Deep white matter
1 12 3 7 2 24
2 1 1 1 1 4
3
4
Subtotal 13 4 8 3 28
Periventricular white matter
1 4 2 1 7
2 2 2
3 1 1
4
Subtotal 7 0 2 1 10
Total
1 32 10 24 9 75
2 12 1 8 2 23
3 1 1 2
4 2 2
Total 45 13 33 11 102signals on T1- and T2-weighted imaging with or with-
out surrounding edema that had been absent in previ-
ous MRI images were newly identified in six patients.
Changes in total CH score according to time after
initial brain irradiation treatment are shown in
Figure 4. Over the 5-year observation period, 23 of
the 28 patients (82.1%) had an increase in total CH
score, by 1-10 points. Three patients exhibited a tran-
sient increase in total CH score, possibly reflecting ar-
tifacts of T2*-weighted MRI. In terms of grading
classification, three patients progressed from grade I
to grade II, and three progressed from grade II to grade
III during the 5-year observation period.
Clinical Symptoms
Two patients experienced episodes of vertigo and
headache and bleeding from CH at the cerebellum
that was diagnosed by conventional MRI at other hos-
pitals. CH grade was I (total score 4) in one of these pa-
tients and III (total score 15) in the other. One patient
had frequent headaches and CH (grade III; total score
15) detected just before enrolling in this study. An-
other patient had hand numbness and was diagnosed
withCH (grade IV, total score 6) at our hospital, where
MRI and computed tomography (CT) scan revealed
a giant CH in the right basal ganglia (Figure 5). Con-
sultation with a neurosurgeon resulted in periodical
MRI examinations and careful follow-up. Exacerba-
tion of symptoms has not been observed during the
subsequent 5 years, but the patient’s total CH score in-
creased from 6 to 7 because of a new lesion found in the
left frontal lobe. All other patients with CH lesions de-
tected in this study were asymptomatic throughout the
follow-up period.
Venous Angioma
Venous malformation or angioma was not de-
tected on contrast MRI with gadolinium-chelates in
any of the patients with or without CH changes.DISCUSSION
RICH of the brain was first recognized as a late ef-
fect of radiation therapy for brain tumors using high-
dose irradiation (50-60 Gy). This effect is commonly
seen in children treated with radiation therapy for rea-
sons other than brain tumors. Progress in diagnostic
Figure 3. Total CH scores according to total cranial radiation dose be-
fore and/or during conditioning treatment for HSCT. Total CH scores
between 0 Gy and 6-12 Gy, between 0 Gy and 18-36 Gy, and between
6-12 Gy and 18-36 Gy were statistically significantly different. *P \
.001, Mann-Whitney U test.
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detection of RICH. However, little is known about
the incidence, dose relationship, localization, natural
course, and clinical symptoms in HSCT recipients,
in whom radiation is often used as a part of chemother-
apy for leukemia or as TBI in conditioning.
Strenger et al [15] reported that eight of 171 pedi-
atric patients who underwent cranial radiation at 9 to
85.6 Gy at age 10.5 months to 38.5 years (median,
8.3 years) developed CH at 2.9 to 18.4 years after irra-
diation, with a cumulative incidence of 6.74% at 20
years after radiation therapy. In that study, CT or con-
ventional MRI without T2*-weighted imaging was
used to diagnose CH. Koike et al [16] reported that
18 of 90 children (20%) who had received 18 to 66
Gy of cranial radiation at age 0-17 years (mean, 7.2
6 4.5 years) developed CH at 2 to 10 years after the
initial irradiation.
In the present study, 28 of 68 long-term adult sur-
vivors of childhood HSCT (41.2%) were diagnosed
with CH, and the probability of developing CH by
25 years after HSCT was 61.5% 6 9.1%. Given that
the incidence of intracranial cavernous malformations
is approximately 0.5% in the general population, theFigure 4. Changes in total CH scores during the 5-year obfrequency and probability in our series apparently ex-
ceed this range. Because CH was not found in patients
who had not received radiation to the head before and/
or during the conditioning regimen for HSCT, radia-
tion was considered the cause of CH in those survivors.
CH was found in no patients who did not receive
cranial radiation (n 5 19), in 46.2% of those who
received 6 to 12 Gy (n 5 39), and in 100% of those
who received 18 to 36 Gy (n 5 10). Thus, 6 to 12
Gy might be considered the threshold level for devel-
opment of RICH, and higher radiation dose was sig-
nificantly associated with a higher frequency of RICH.
Younger age has been reported as a risk factor for
RICH by several authors. However, this association
with younger age was not found in the present study,
and CH developed at a slightly higher frequency in
children aged .15 years at the time of radiation ther-
apy. This higher incidence in the oldest age group was
considered related to the higher total cranial radiation
dose received by this group.
Naturally occurring CH is known to be associated
with developmental venous malformation (DVM) or
angioma (DVA), which is usually occult and detected
during surgery or at autopsy, with a crude detection
rate of 0.43 per 100,000 adults per year [17]. Abdulrauf
et al [18] reported DVM in 24% of patients with
CH, and DVA is reportedly associated with cavernous
malformation in 8% to 33%of cases [19]. DVAwas not
found in our patients on contrast MRI; susceptibility-
weighted MRI might be more sensitive for detecting
DVA. Thus, the causative association of DVM and
CH is less likely in our patients.
Cox multivariate regression analysis identified cra-
nial radiation dose as the sole factor affecting the devel-
opment of CH in our analysis. However, other factors,
such as intrathecal therapy or certain chemotherapies,
might have contributed to the development of late
changes in neurologic function and may be related to
the imaging changes to some extent. We could not
analyze such factors, however, because we could not
collect all of these data from the referring hospitals.
T2*-weighted MRI was sensitive and useful in
the early detection of CH. Maeda et al [20] judgedservation period in the patients who developed RICH.
Figure 5. MRI and CT images in a patient with a giant CH. (A) T1-weighted MRI. (B) T2-weighted MRI. (C) T2*-weighted MRI. (D) CT.
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weighted MRI in detecting the number and distribu-
tion of lesions in CH. In our analysis, small lesions
were identified only on T2*-weighted imaging, not
on conventional T2-weighted imaging, likely contrib-
uting to the higher incidence in the present study com-
pared with previous reports.
The onset of CH detected by T2*-weighted MRI
ranged from 9 to 24 years after HSCT and also from
9 to 24 years after the first radiation treatment, whereas
diagnosis of CH by conventional T2-weighted MRI
was delayed or not possible in most cases. Because
CH changes were already present in most survivors
at the time of initial MRI, actual onset was considered
to be earlier. Thus, the present study has a limited abil-
ity to precisely detect the onset of RICH.
As in previous reports of RICH, the most common
localization of hemangioma was supratentorial, partic-
ularly in the subcortical and deep white matter. Infra-
tentorial lesions were found predominantly in the
cerebellum, which might have caused clinical symp-
toms, such as vertigo or headache, in a few patients.
The CH scoring system that we have developed is
useful for quantifying lesions and evaluating changes
occurring during the follow-up period. Increased
CH scores were seen in 23 of 28 patients (82.1%)during the 5-year observation period. Thus, this study
reveals details of the course and speed of CH growth
through annual follow-up examinations. The use of
this scoring method could also provide insight into
the pathogenesis and natural course of RICH,
although the method’s clinical relevance remains un-
certain given the small number of patients and short
follow-up period of the present study.
In general, RICH lesions neither disappear nor
diminish over their natural course. However, a de-
crease in CH score after a transient increase was seen
in three patients during the study period. This tran-
sient increase in CH score was considered related to
an artifact of T2*-weighted MRI. Evaluation by
single-time point MRI may carry a risk of overestima-
tion, and thus careful evaluation by serial MRI over
sufficient intervals is necessary.
Despite the progression of some CH lesions, most
patients remained asymptomatic, as in previous re-
ports. Newly recognized signal changes on T1- and
T2-weightedMRIwith or without surrounding edema
of preexisting CH are considered to reflect bleeding
episodes during the intervals between examinations,
and repeated bleeding may finally form a mass lesion.
Symptomatic bleeding may occur with or without
triggers that cause a rapid increase in blood pressure,
Biol Blood Marrow Transplant 18:1090-1098, 2012 1097RICH after HSCThowever. Pregnancy and labor are known risk factors
for such bleeding [21], probably because the angio-
genic process is initiated by growth factors, such as
vascular endothelial growth factor, basic fibroblast
growth factor, and placental growth factor [22]. We
treated a case of seizure caused by CH bleeding during
labor in a 31-year-old female who had a history of
cranial radiation of 18 Gy for acute lymphoblastic leu-
kemia in childhood. Her CH grade was IV with a mass
effect at the right parahippocampal gyrus, and her total
CH score was 23. This patient was not included in the
present study because she had no history of HSCT.
We suggest that MRI, including T2*-weighted
imaging, should be routinely and serially performed
over the long term in those who have received radiation
to the head during childhood or adolescence. Attention
should also be given to patients in whom RICH was
identified, especially those with grade III/IV CH,
regardless of the localization of lesions, or those with
grade I/II CH with infratentorial lesions, given that
infratentorial CH ismore closely associatedwith symp-
tomatic bleeding compared with supratentorial CH
[23,24]. Information on the presence of RICH will
aid accurate diagnosis in those survivors and facilitate
proper management in the event of clinical bleeding
episodes. Surgical indications in those with repeated
bleeding episodes and progressive neurologic symp-
toms should be discussed with a neurosurgeon.
Routine and serialMRI is useful for early detection
of other well-recognized brain imaging changes, such
as mineralizing microangiopathy, leukoencephalop-
athy, and brain tumors [25]. Meningioma was detected
in eight patients with cranial radiation (five with RICH
and three without RICH), and oligoastrocytoma was
detected in one patient with cranial radiation and
RICH and will be reported separately.
Although we have clarified the high incidence and
the importance of RICH in adult long-term survivors
of HSCT performed during childhood in a single-
center study, the mechanisms of RICH remain un-
known. Retrospective and multicenter studies using
sensitive T2*-weighted MRI on long-term survivors
of childhood cancer who received radiation to the skull
should be planned to confirm the actual incidence of
RICH in a larger population. Prospective and long-
term studies on those who received radiation to the
head during treatment are needed to examine the onset
and natural course of RICH.
In conclusion, because all of our patients with CH
had a history of radiation therapy to the brain, and
because none of the patients who did not receive radi-
ation therapy developed CH, the cause of CH in those
adult survivors of childhood HSCT was considered to
be radiation. We found a dose-reponse relationship
between total cranial radiation and the development
of CH and determined that the radiation dose of 6 to
12 Gy commonly used in patients undergoingHSCT could cause RICH. Careful and long-term
evaluation with MRI, including T2*-weighted imag-
ing, is strongly recommended in HSCT recipients
who received radiation therapy before and/or during
HSCT. This is the first report of a high prevalence
of RICH among long-term HSCT survivors, in which
radiologic changes were quantitatively and longit-
udinally evaluated by annual MRI, including
T2*-weighted imaging.ACKNOWLEDGMENTS
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